Welcome to the stock market today! With novel coronavirus cases and hospitalizations rising, all attention is on the pandemic. However, there is some good news. Investors have received updates from Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX) and Eli Lilly (NYSE:LLY). As today progresses, keep these treatments and others on your radar. Latest Updates:
Not too long ago, I offered a very strong buy recommendation for next-gen, solid-state battery maker Quantumscape (NYSE:QS). At the time, QS stock was trading at $65 and change. Source: nrqemi / Shutterstock.com Five days later, the stock shot up to its all-time high price of $132.73. But to be honest, I think I got lucky
The shares of Opendoor Technologies (NASDAQ:OPEN) have trended lower since they began trading on Dec. 18. That sets the stock apart from many companies that have recently gone public, a large number of which have soared after going public. However, I think investors may be right about Opendoor stock. I don’t expect the company to
If there was ever coverage on a particular company that could be classified as almost exclusively low-hanging fruit, DoorDash (NYSE:DASH) would be it. Frankly, when you peruse the blogosphere, everyone’s writing the same article: DoorDash stock enjoyed the benefits of a supercharged initial public offering but once the euphoria fades, shares will crumble. Great but
Moderna (NASDAQ:MRNA) is reaping the rewards of its successful Covid-19 vaccine, pushing MRNA stock higher and higher. It is now winning more contracts to deliver its vaccine and analysts are taking note. Source: Ascannio / Shutterstock.com And the stock has been climbing. Especially since the FDA approved its Covid-19 vaccine on Dec. 18 for emergency
Once we get back to normal, one of the technologies you should truly advantage is global air travel. Having visited many parts of the world, I’ve gained an education that you can’t get from textbooks. And one of the lessons I’ve learned is that when it comes to foreign policy, Americans are probably the most
It’s been about two years since Moderna (NASDAQ:MRNA) came public. The company raised $604 million at a $7.5 billion valuation. But the first-day return for MRNA stock was a dud. The return was an awful -19%. Source: Ascannio / Shutterstock.com At the time, there were concerns about the vaccine market, which has traditionally been challenging.
A few weeks back, I said to fade the big rally in Sundial Growers (NASDAQ:SNDL). But now, after its pullback from 75 cents to 45 cents per share, there may be opportunity in SNDL stock for those with a high risk appetite. No, not due to the fact this penny stock has fallen further below